Indometacin transdermal - NAL Pharma

Drug Profile

Indometacin transdermal - NAL Pharma

Alternative Names: Indomethacin transdermal - NAL Pharma; NAL 1207

Latest Information Update: 26 Aug 2016

Price : $50

At a glance

  • Originator NAL Pharma
  • Class Analgesics; Antirheumatics; Chlorobenzenes; Indoles; Nonsteroidal anti-inflammatories; Small molecules
  • Mechanism of Action Cyclo-oxygenase 1 inhibitors; Cyclo-oxygenase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Clinical Phase Unknown Pain

Most Recent Events

  • 26 Aug 2016 Chemical structure information added
  • 11 Aug 2016 Indometacin transdermal - NAL Pharma is available for licensing as of 11 Aug 2016. http://www.nalpharma.com/licensing.php?id=5&lang=en
  • 11 Aug 2016 Clinical trials in Pain (Transdermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top